The cell growth, morphology and immunocytochemistry of novel cell line established from a bone marrow of the patient with therapy-related myelodysplastic syndrome, entitled PC-MDS

We report on cell growth, morphology, and immunocytochemistry of the first human cell line, PC-MDS, derived from a bone marrow of a patient with therapy-related myelodysplastic syndrome who had no overt leukemia post-MDS phase. This cell population consisted of fast-growing mononuclear cells. Standard cytochemistry methods for detection of MPO, lipids, glycogen and ANAE gave results as follows: MPO and SBB negative while PAS and ANAE positive. Positive cytochemical staining and immunophenotype analyses indicated that PC-MDS cells have some characteristics of the early myeloid precursor cell. As the first t-MDS derived cell line it could be a new tool in evaluation of complex biology of MDS and also serves as a model for diverse in-vitro research. treatment [1] options for various malignancies including myelodysplastic syndrome (MDS). MDS are heterogeneous group of clonal hematopoietic stem cell disorders, characterized by ineffective hematopoiesis, and impaired maturation of hematopoietic cells, progressive cytopenias, and an increased risk of developing acute myeloid leukemia (AML) [2]. Natural history of MDS ranges from indolent chronic course to rapid leukemic progression [3-8]. Continuous malignant hematopoietic cell lines have been established from the whole spectrum of MDS variants and from different stages of the disease. Drexler [1] recently reported on 10 cell lines derived from the various MDS subtypes and 17 cell lines from the patients with post-MDS leukemia. Among MDS subtypes-derived cell lines only one cell line was derived from the patient with therapy-related MDS/AML (t-MDS/ t-AML) [9]. We here described cell growth, morphology and immunocytochemistry characteristics of the first human cell line obtained in our laboratory. Cell line was derived from a bone marrow of a patient with t-MDS who had no overt signs or symptoms of post-MDS leukemia.